Arbor Trust Wealth Advisors LLC Purchases 127 Shares of Stryker Co. (NYSE:SYK)

Arbor Trust Wealth Advisors LLC grew its position in shares of Stryker Co. (NYSE:SYK) by 1.1% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 12,101 shares of the medical technology company’s stock after purchasing an additional 127 shares during the quarter. Stryker makes up about 2.0% of Arbor Trust Wealth Advisors LLC’s investment portfolio, making the stock its 19th largest position. Arbor Trust Wealth Advisors LLC’s holdings in Stryker were worth $4,367,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Dunhill Financial LLC increased its position in Stryker by 94.9% during the 3rd quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock valued at $27,000 after buying an additional 37 shares in the last quarter. Centennial Bank AR lifted its holdings in shares of Stryker by 106.7% during the 2nd quarter. Centennial Bank AR now owns 93 shares of the medical technology company’s stock valued at $32,000 after buying an additional 48 shares during the period. Darwin Wealth Management LLC purchased a new position in Stryker in the third quarter worth about $36,000. Hara Capital LLC purchased a new stake in shares of Stryker during the 3rd quarter valued at about $42,000. Finally, HBW Advisory Services LLC purchased a new position in shares of Stryker during the 3rd quarter worth $42,000. 77.09% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the stock. Canaccord Genuity Group increased their price objective on shares of Stryker from $360.00 to $400.00 and gave the company a “buy” rating in a report on Wednesday, October 30th. StockNews.com upgraded shares of Stryker from a “hold” rating to a “buy” rating in a research report on Thursday, January 9th. BTIG Research increased their price objective on shares of Stryker from $383.00 to $394.00 and gave the company a “buy” rating in a research report on Wednesday, October 30th. Piper Sandler restated an “overweight” rating and set a $420.00 target price (up from $380.00) on shares of Stryker in a research report on Wednesday, October 30th. Finally, Truist Financial lifted their price target on Stryker from $380.00 to $409.00 and gave the stock a “hold” rating in a research report on Wednesday, December 18th. Four research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $405.80.

Insider Transactions at Stryker

In other Stryker news, CEO Kevin Lobo sold 57,313 shares of the business’s stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $368.70, for a total transaction of $21,131,303.10. Following the completion of the transaction, the chief executive officer now owns 100,027 shares in the company, valued at $36,879,954.90. The trade was a 36.43 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 5.50% of the company’s stock.

Stryker Stock Performance

SYK opened at $383.91 on Friday. Stryker Co. has a twelve month low of $307.23 and a twelve month high of $398.20. The firm has a market capitalization of $146.35 billion, a PE ratio of 41.15, a PEG ratio of 2.51 and a beta of 0.95. The company has a current ratio of 1.91, a quick ratio of 1.22 and a debt-to-equity ratio of 0.66. The firm’s 50-day moving average price is $375.51 and its 200 day moving average price is $358.81.

Stryker (NYSE:SYK) last posted its earnings results on Tuesday, October 29th. The medical technology company reported $2.87 earnings per share for the quarter, beating the consensus estimate of $2.77 by $0.10. Stryker had a net margin of 16.34% and a return on equity of 23.07%. The company had revenue of $5.49 billion for the quarter, compared to analyst estimates of $5.37 billion. During the same period in the previous year, the business posted $2.46 EPS. Stryker’s revenue was up 11.9% on a year-over-year basis. As a group, sell-side analysts expect that Stryker Co. will post 12.06 EPS for the current fiscal year.

Stryker Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Tuesday, December 31st will be paid a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a yield of 0.88%. This is a boost from Stryker’s previous quarterly dividend of $0.80. The ex-dividend date is Tuesday, December 31st. Stryker’s dividend payout ratio is 36.01%.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.